Faricimab Outperforms High-Dose Aflibercept in Fluid Reduction at 12 Weeks

By News Health
1 month Ago

(MedPage Today) — Faricimab (Vabysmo) showed greater fluid reduction compared with high-dose aflibercept (Eylea) at 12 weeks in matched analyses of diabetic macular edema (DME) and age-related macular degeneration (AMD) studies presented at the…

Source link : https://www.medpagetoday.com/meetingcoverage/arvovideopearls/115798

Author :

Publish date : 2025-05-29 14:23:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

New Type of Hypertension Medicine; ED Boarding in Older Adults

Who Will Fill the 988 Hotline Gap for LGBTQ+ Youth?

Ketamine helped me escape my negative thoughts

Ancient mass extinction shows how Earth turned into a super-greenhouse

Cyberattacks could exploit home solar panels to disrupt power grids

We finally understand why quasicrystals can exist